Return to homepagePandemic Pact

RUX-COVID: A single arm open-label clinical study to investigate the efficacy and safety of Ruxolitinib for the treatment of COVID-19 pneumonia

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    LifeArc

  • Research Location

    United Kingdom

  • Lead Research Institution

    University Health Network

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Phase 1 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase I

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

A two-stage Phase 2 trial to investigate if a JAK inhibitor can halt the progression of COVID-19 and avoid the need for a ventilator. Ruxolitinib, a JAK inhibitor currently used to treat myelofibrosis, a rare form of blood cancer, will be tested in 20 hospitalised patients in Ontario. Once results of Stage 1 are available, a further group of patients will be enrolled into Stage 2. The team will collaborate on the analysis of patients' samples with Dr Shahram's Kordasti's team at King's College, London who is also conducting a trial with ruxolitinib.